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Introduction
Recent randomized studies showed that epidermal growth 
factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) 
significantly improved the progression-free survival (PFS) 
of advanced non-small cell lung cancer (NSCLC) harboring 
activating EGFR mutations, compared to chemotherapy 
(1-3). Conversely, TKIs do not offer any benefit to EGFR 
wild-type patients (1). 
Collecting proper tissue samples is the key issue for 
molecular analyses, although it is not always an easy task, 
particularly in advanced NSCLC (4). Therefore, a blood 
draw could provide an alternative source of tumor samples.
In NSCLC, circulating tumor cells (CTCs) and 
circulating tumor DNA (ctDNA), simultaneously present in 
patients’ blood, could broaden, in concert, our knowledge 
on tumor characteristics and behavior. In particular, these 
biomarkers can be useful to detect “druggable” mutations 
and monitor TKIs, thus improving the prognosis (5).
CTCs can form metastases and, in NSCLC, they express 
both epithelial and mesenchymal markers (6). Regarding 
cell-free DNA (cfDNA), its concentration and/or tracking 
specific tumor mutations (ctDNA) could be used to monitor 
treatment effectiveness (7). 
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To obtain a more comprehensive view of the circulating 
cells, we investigated both epithelial cell adhesion molecule 
(EpCAM)-positive and EpCAM-low/negative cells, 
and evaluated in both subsets 2 cytokeratin-profiles. By 
monitoring CTCs and ctDNA at multiple time points 
throughout the care, we could reveal important information 
on disease evolution.
Through  a  s ing le - tube  procedure ,  th i s  work 
demonstrated how and when these actors of liquid biopsy 
could be useful to improve the clinical management of the 
patient.
Materials and Methods
Blood samples
Blood samples were collected upon informed consent 
(IOV-IRCCS study “Individualized treatment of patients 
with advanced NSCLC: potential application for CTCs 
molecular and phenotypical profiling”, NCT02407327).
We collected serial blood samples at baseline, at the end 
of the first and second cycle of therapy, after radiological 
assessment, after surgery before starting the new treatment 
and after 6 months of post-surgery adjuvant treatment. 
At each time point, we performed the quantification 
of EpCAM-positive and EpCAM-low/negative cells. 
Furthermore, we analyzed ctcDNA and cfDNA by droplet 
digital PCR (ddPCR) to disclose the allele frequency of 
EGFR L858R and T790M.
Detection of EpCAM-positive and EpCAM-low/negative 
CTCs 
We enumerated EpCAM-positive CTCs in whole blood 
with the CellSearch System (CS) (Menarini, Italy) according 
to the manufacturer’s instructions and user’s guidelines 
[standard assay (SA)] (8).
Furthermore, to investigate the full cytokeratin (CK) 
profile of NSCLC CTCs, we integrated the CTC assay, as 
previously described, using the CXC Kit (Menarini, Italy) 
with FITC-conjugated anti-CK7, -CK14 (clone LP5K and 
LL002, respectively, Millipore, Billerica MA, USA), and 
anti-C11 (clone C11, ACZON, Bologna, Italy) [expanded 
assay (EA)] (9).
EpCAM-low/negative cells were collected downstream 
of the CellSearch processing, using a 5 µm-pore microsieve 
membrane (VyCAP, Deventer, The Netherlands), as 
previously described (10). 
The cells on microsieve were stained using a cocktail of 
fluorescently labelled antibodies, namely: FITC-conjugated 
detecting CK1-10,  13–16,  18,  and 19 (AE1/AE3, 
eBioscience; C11, ACZON), APC-conjugated anti-CD16 
and -CD45 (Invitrogen), and DAPI for nuclear staining (SA). 
The EA also included CK7 and 14 (Millipore) antibodies. 
Cells were scored as DAPI+CK+CD45−CD16−, with a 
minimum cell size of 4 µm × 4 µm, and a nucleus occupying 
at least 50% of the CK+ cytoplasm.
DNA whole genome amplification (WGA) from CTCs 
The content of the CS cartridge was subjected to WGA 
with Ampli1-WGA Kit (Menarini Silicon Biosytems, 
BO, Italy) according to the manufacturer’s instructions. 
Similarly, EpCAM-low/negative cell DNA was extracted 
using the QIAmp DNA Micro Kit (QIAGEN, Hilden, 
Germany), following the manufacturer’s protocol, and 
subjected to WGA.
Circulating cfDNA 
The EDTA blood samples were centrifuged at 1,600 g 
for 10 minutes, followed by 16,000 g for another 10 
minutes, and the plasma supernatant was stored at −80 ℃ 
until analysed. Plasma DNA was purified with QIAamp 
Circulating Nucleic Acid Kit (Qiagen, Valencia, CA, USA), 
as recommended by the manufacturer. The extracted DNA 
was stored at −80 ℃.
ddPCR assays
Allele frequency of EGFR L858R and T790M was 
measured with the QX200 droplet digital PCR system by 
the commercial PrimePCR ddPCR mutation assays. The 
data was acquired and analysed by QuantaSoft analysis 
software version 1.7.4 (BioRad, Hercules, CA, USA).
Results
Clinical history
In November 2015, a 65-year-old male, former smoker 
came to our unit reporting chest pain and exertional 
dyspnea.
The patient underwent a CT scan showing a lung mass 
of 5.5 cm located in the upper left lung (Figure 1A); the 
neighboring mediastinal lymph nodes were involved. We 
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Figure 1 Imaging and liquid biopsy monitoring. (A) CT scan of the initial evaluation, exhibiting lung mass located on the left upper lobe 
(5.5 cm × 3 cm, red arrow); (B) CT scan, performed immediately before surgery, showing a reduction in the lesion size (2.3 cm × 1.2 cm, 
red arrow); (C) PET-CT imaging showing relapse of tumor involving mediastinal lymph nodes; (D) PET-CT, carried out in November, 
showing a good response after radiotherapy; (E) longitudinal graphs of the four CTC subpopulations, namely EpCAM-positive SA, 
EpCAM-positive EA, EpCAM-low/negative SA, and EpCAM-low/negative EA. The ctDNA and CTC mutational status are also shown 
for L858R and T790M mutations at the different time points, namely: t0 = baseline, t1 = after one cycle of therapy, t2 = after two cycles of 
therapy, t3 = before lobectomy, t4 = after lobectomy, t5 = in conjunction with PET, after the end of radiotherapy. CTC, circulating tumour 
cells; PET, positron emission tomography; CT, computed tomography; SA, standard assay; EA, expanded assay; EpCAM, epithelial cell 
adhesion molecule; ctDNA, circulating tumour DNA; cfDNA, cell-free DNA; mut, mutant; wt, wild type. 
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performed a bronchoscopy, with bronchial biopsies. The 
immunohistochemistry revealed a P63-negative, TTF-1-
positive adenocarcinoma. The mutation status in bronchial 
specimen was EGFR and ALK negative.
Based on this, we planned neo-adjuvant treatment (cis-
platinum + vinorelbine). The patient showed a partial 
response (PR) according to RECIST 1.1 criteria (11) 
(Figure 1B), and then underwent surgical lobectomy. The 
surgical sample showed EGFR exon 21 mutation (L858R). 
According to NCCN guidelines, the patient received 
three cycles of cisplatin and vinorelbine, as adjuvant 
treatment, until May 2016 (12).
In August 2016 however, an FDG-PET-CT documented 
disease progression in perihilar region of left lung 
(Figure 1C).
The patient began a second-generation TKI treatment 
(afatinib 40 mg/day). Two months later, the magnetic 
resonance imaging (MRI) documented brain metastasis 
that we treated with stereotactic radiotherapy, along with 
mediastinum radiotherapy. According to the last FDG-PET-
CT, in February 2017, the patient showed stable disease 
(SD) (Figure 1D), only paratracheal lymph nodes being 
metabolically active.
Table 1 compares clinical-pathological characteristics, 
treatments and imaging reports throughout the continuum 
of the care, with findings obtained through liquid biopsy.
EpCAM-positive CTCs, EpCAM-low/negative CTCs and 
ctDNA 
Concerning CTCs, we noticed a saw-toothed count pattern 
in longitudinal graphs for all four subpopulations, EpCAM-
positive SA and EA and EpCAM-low/negative EA and SA 
(Figure 1E). At baseline (t0), we only found EpCAM-positive 
CTCs (both EA and SA), while the EpCAM-low/negative 
subpopulation emerged after the first cycle of chemotherapy, 
when the EpCAM-positive subpopulation disappeared (t1); 
interestingly, after the next cycle of therapy, the EpCAM-
positive EA subpopulation reappeared (t2). 
Notably, we highlighted the highest level in all CTC 
subgroups immediately before lobectomy (t3), while they 
were undetectable after lobectomy and 3 cycles of adjuvant 
+ cis-platinum + vinorelbine (t4). Simultaneously, we 
analyzed by ddPCR the presence of EGFR mutated ctDNA 
at every time point, and DNA of CTC-positive samples, 
both EpCAM-positive and EpCAM-low/negative.
We found L858R positive ctDNA at baseline (t0), after 
two cycles of therapy (t1) and at lobectomy (t4). 
Interestingly, the mutational profile of CTCs also 
changed during treatment: at baseline (t0), in the EpCAM-
positive fraction, we found the EGFR L858R mutation 
that was undetectable in the biopsy specimen using 
Sanger Sequencing. We documented the same mutation 
in EpCAM-positive EA CTCs after two cycles of therapy 
(t3) and at the last point of observation (t5). Conversely, 
EpCAM-low/negative CTCs were always negative for 
L858R. The CTC and ctDNA samples analyzed were all 
negative for the T790M mutation.
Curiously,  when CT showed a PR (Table 1  and 
Figure 1B,D), we noticed the presence of at least one CTC 
subpopulation; moreover, EpCAM-positive and EpCAM-
low/negative CTCs persisted at the last time point (t5).
Discussion 
The main challenge of targeted therapies in NSCLC, 
as well as in other malignancies, is tracking the disease 
dynamics to measure the effectiveness of treatment and to 
anticipate a change of therapy, when appropriate. Here, 
we demonstrated, through serial sampling of an individual 
patient, how the analysis of the different components of 
liquid biopsy could shed light on the tumor strategy to 
escape treatment.
Indeed, during platinum-based chemotherapy, the 
tumor releases EpCAM-low/negative CTCs; consistently 
with previous reports in others malignancies, where this 
treatment seems to recruit EMT-like CTCs (13,14). 
However, the EpCAM-positive subpopulation reappeared 
at the end of the second cycle of therapy; this could imply 
an escape strategy of the disease and the coexistence of 
different CTC subpopulations. 
Interestingly, at the last time point, when radiological 
control referred SD, we observed EpCAM-positive 
and EpCAM-low/negative cells, and found the L858R 
mutation in EpCAM-positive CTCs. On the one hand, 
we should not underestimate the presence of different 
subpopulations of CTCs in conjunction with a PR, 
especially if we consider that these cells represent an 
intermediate step toward metastasis. On the other hand, 
the fact that at least one of them is carrying an activating 
EGFR mutation demonstrates that TKIs are of potential 
benefit in this patient, as documented by the long-term 
control of his disease that we obtained with afatinib, from 
February 2017 until now. A consensus exists that CTCs are 
heterogeneous and could allow real-time tracking of the 
tumor transient states. Moreover, CTCs could show the 
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Table 1 Imaging reports, tumor specimen mutational status, therapy and EpCAM pos and low/neg CTC counting of the patient 
Date
Imaging  
pathological  
evaluation
Tumor specimen  
mutational analysis  
(Sanger sequencing)
Therapy CTC SA CTC EA
CTC  
EpCAM-SA
CTC  
EpCAM-EA
11/17/2015 Bronchoscopy with 
biopsy
EGFR wt (30% of neoplastic 
cells)
– – – – –
11/20/2015 PET: PD, LN – – – – – –
12/16/2015 – – Neo-adjuvant +  
cisplatinum + vinorelbine
1 1 0 0
01/20/2016 – – – 0 0 0 3
02/10/2016 – – – 0 3 NA 0
02/17/2016 – – End neo-adjuvant +  
cisplatinum + vinorelbine
– – – –
03/02/2016 CT: PR – – – – – –
03/24/2016 – – – 1 3 2 6
03/30/2016 – – Lobectomy – – – –
05/18/2016 – – Adjuvant + cisplatinum  
+ vinorelbine (3 cycles)
0 0 0 0
05/31/2016 – EGFR ex21 L858R in surgical 
lobectomy tissue
– – – – –
06/15/2016 – – Adjuvant + cisplatinum  
+ vinorelbine (3 cycles)
– – – –
08/12/2016 PET: PD (bone and 
lung)
– – – – – –
09/05/2016 – – Afatinib – – – –
10/17/2016 PET: PD (CNS) – – – – – –
11/14/2016 PET – – – – – –
11/17/2016 – – Radiotherapy – – – –
11/30/2016 PET: PR – – 0 1 2 0
PD, progression disease; LN, lymph node; PR, partial response; CNS, central nervous system; NA, not available; CTC, circulating  
tumour cells; EpCAM, epithelial cell adhesion molecule; PET, positron emission tomography; CT, computed tomography; wt, wild type; SA,  
standard assay; EA, expanded assay.
spectrum of mutations and/or protein expression alterations 
present in cancer. Indeed, we noted here that the four CTC 
subpopulations allow the monitoring of the different steps 
of cancer evolution in response to treatment.
Furthermore, we observed a slight discordance about 
the L858R detection timing between the golden standard 
analysis of tumor specimens, CTCs and ctDNA. 
Discrepancy between mutational status as documented 
in bronchial biopsies and surgical sample after lobectomy, 
is not surprising and we can easily explain it, because of 
a limited sampling offered by bronchial biopsies. Indeed, 
at this regard, cfDNA, intended as the sum of different 
neoplastic lesions present at any time in individual patient, 
seems to be more advantageous, when highly sensitive 
technique has been using to detect L858R, as ddPCR in 
our case report. At this regard, we should reflect about the 
superiority of ctDNA in choosing target treatment, also 
when bronchial specimens give negative results. 
However, our findings do not support the superiority of 
ctDNA at any time of patient’ monitoring. For example, 
E575Journal of Thoracic Disease, Vol 10, No 7 July 2018
© Journal of Thoracic Disease. All rights reserved. J Thorac Dis 2018;10(7):E570-E576jtd.amegroups.com
before lobectomy (t3), when likely chemotherapy affected 
the release of CTCs in the blood stream, we could detect 
EGFR mutation in EpCAM-positive tumor cells, but not in 
ctDNA. Indeed, it is conceivable that changing level of few 
cells, did not affect the total amount of ctDNA to result in 
EGFR detection by using this technique, whereas ctcDNA 
investigation was more useful at that time.
This finding suggests the complementary use of these 
tests (15): taking them together, in this patient they better 
reflected spatial and temporal heterogeneity of the tumor 
under the selective pressure of treatment.
To date, the development of resistance in cancer cells, 
acquired via clonal evolution during treatment, represents 
the main challenge of a successful targeted therapy. To 
bypass this bottleneck, an element of the utmost importance 
is an accurate design of the therapeutic strategy. However, 
to achieve this goal, we need robust biomarkers for serial 
tumor profiling (16). Indeed, high effort has been made, so 
far, to standardize and validate, in clinic, consensus analyses 
of liquid biopsy, as CTCs and ctDNA/miRNA, by several 
scientific consortia [e.g., STALKLUNG01, AIR Study 
Consortium (17), or CANCER_ID, www/cancer-id/eu], so 
that we are confident to receive soon advanced remarks at 
this regard.
In our study, the actors of liquid biopsy and their specific 
characteristics disclosed a polyclonal resistance that could 
allow up-front, combination therapy to prolong treatment 
response.
It still has to be clarified, in further larger studies, how 
the CTC subgroups join forces in high-risk patients. In the 
future, we might use this information to design a tailored 
therapeutic strategy to hinder the continuous tumor 
evolution.
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